SOPHiA GENETICS & MD Anderson Launch Collaboration to Advance AI-Driven Precision Oncology

As part of the initiative, the two organizations will co-develop an advanced next-generation sequencing (NGS) oncology test leveraging SOPHiA GENETICS’ SOPHiA DDM™ Platform.

SOPHiA GENETICS, a leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to integrate AI analytics with clinical expertise in cancer care.

The partnership will focus on tools that interpret complex diagnostic data to support treatment decisions.

As part of the initiative, the two organizations will co-develop an advanced next-generation sequencing (NGS) oncology test leveraging SOPHiA GENETICS’ SOPHiA DDM™ Platform. The AI-powered platform is designed to analyze multimodal molecular data, enabling clinicians to rapidly interpret RNA-sequencing results for accurate diagnosis and treatment guidance.

MD Anderson researchers will utilize SOPHiA GENETICS’ AI technologies to build bioinformatics pipelines aimed at translating high-dimensional molecular information into actionable insights. The collaboration also includes a series of research and development programs focused on characterizing tumor evolution in real time, ensuring reliability and reproducibility in genomic testing, and optimizing patient-specific clinical trial opportunities.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” said Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

The collaborative research at MD Anderson will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor, both in the Division of Pathology and Laboratory Medicine.

Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer of SOPHiA GENETICS, added, “With SOPHiA DDM™ as a unifying analytical layer, we are enabling discoveries, accelerating breakthroughs in precision oncology, and helping patients worldwide benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

Stay tuned for more such updates on Digital Health News